June 2026 in “Cell Transplantation” Stem cell therapies show promise for treating hair loss.
June 2026 in “Saudi Medical Horizons Journal” JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.
May 2026 in “International Journal of Homoeopathic Sciences” Individualized Homeopathic Medicine shows promise for treating alopecia with lasting hair regrowth.
April 2026 in “Indian Journal of Dermatology” PRP and IT are equally effective for treating localized alopecia areata, but PRP causes more pain and bleeding.
April 2026 in “Skin Appendage Disorders” Exosome therapy shows promise for treating hair loss but needs more research and standardization.
April 2026 in “Preprints.org” Cold Atmospheric Plasma shows promise in treating aggressive breast cancer by targeting cancer cells while sparing normal tissue.
March 2026 in “Preprints.org” DRDE-07 shows promise for treating skin diseases due to its favorable properties.
March 2026 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” Exosome and PRP therapies show promise for treating hair loss but need more research for standardization and safety.
CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.
CD28 is a promising target for treating alopecia areata with belatacept.
CD28 is a promising target for treating alopecia areata with belatacept.
March 2026 in “Journal of Aesthetic Nursing” Combining PRP and minoxidil works best for treating male hair loss.
February 2026 in “Scientific Reports” The gel is safe and effective for treating oral mucositis from chemotherapy and radiation.
February 2026 in “Dermatology and Therapy” Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
February 2026 in “Journal of Dermatological Treatment” CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
January 2026 in “PubMed Central” Clobetasol is more effective than metformin for treating localized alopecia areata.
January 2026 in “International Journal of Innovative Technologies in Social Science” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
January 2026 in “International Journal of Molecular Sciences” Hedgehog pathway inhibitors could be effective in treating melanoma.
January 2026 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Accurate diagnosis is crucial for effectively treating severe alopecia and related symptoms.
CG2001 is safe and well-tolerated for treating hair loss in men.
January 2026 in “MEDS Clinical Medicine” Plum-blossom needle therapy shows promise for treating hair loss but needs more research.
January 2026 in “Dermatologic Therapy” Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
December 2025 in “MEDFARM Jurnal Farmasi dan Kesehatan” Topical metformin shows promise for treating skin conditions like acne and psoriasis.
December 2025 in “Rare Metals” Smart biomaterials and dressings show promise in treating chronic skin diseases by improving drug delivery and minimizing side effects.
December 2025 in “International Journal of Molecular Sciences” Exosome-based therapies show promise for treating alopecia areata but need more research.
December 2025 in “International Journal of Surgery” GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.
December 2025 in “Orvosi Hetilap” Baricitinib is effective and safe for treating alopecia areata.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.